IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v16y2019i22p4334-d284384.html
   My bibliography  Save this article

Pharmacological Therapy of Non-Alcoholic Fatty Liver Disease: What Drugs Are Available Now and Future Perspectives

Author

Listed:
  • Grazia Pennisi

    (Section of Gastroenterology and Hepatology, PROMISE, Policlinico Universitario Paolo Giaccone, Piazza delle Cliniche 2, 90127 Palermo, Italy)

  • Ciro Celsa

    (Section of Gastroenterology and Hepatology, PROMISE, Policlinico Universitario Paolo Giaccone, Piazza delle Cliniche 2, 90127 Palermo, Italy)

  • Federica Spatola

    (Section of Gastroenterology and Hepatology, PROMISE, Policlinico Universitario Paolo Giaccone, Piazza delle Cliniche 2, 90127 Palermo, Italy)

  • Marcello Dallio

    (Department of Precision Medicine, University of Campania Luigi Vanvitelli, via Pansini 5, 80131 Naples, Italy)

  • Alessandro Federico

    (Department of Precision Medicine, University of Campania Luigi Vanvitelli, via Pansini 5, 80131 Naples, Italy)

  • Salvatore Petta

    (Section of Gastroenterology and Hepatology, PROMISE, Policlinico Universitario Paolo Giaccone, Piazza delle Cliniche 2, 90127 Palermo, Italy)

Abstract

The non-alcoholic fatty liver disease (NAFLD) is rapidly becoming the most common cause of chronic liver disease as well as the first cause of liver transplantation. NAFLD is commonly associated with metabolic syndrome (MetS), and this is the most important reason why it is extremely difficult to treat this disease bearing in mind the enormous amount of interrelationships between the liver and other systems in maintaining the metabolic health. The treatment of NAFLD is a key point to prevent NASH progression to advanced fibrosis, to prevent cirrhosis and to prevent the development of its hepatic complications (such as liver decompensation and HCC) and even extrahepatic one. A part of the well-known healthy effect of diet and physical exercise in this setting it is important to design the correct pharmaceutical strategy in order to antagonize the progression of the disease. In this regard, the current review has the scope to give a panoramic view on the possible pharmacological treatment strategy in NAFLD patients.

Suggested Citation

  • Grazia Pennisi & Ciro Celsa & Federica Spatola & Marcello Dallio & Alessandro Federico & Salvatore Petta, 2019. "Pharmacological Therapy of Non-Alcoholic Fatty Liver Disease: What Drugs Are Available Now and Future Perspectives," IJERPH, MDPI, vol. 16(22), pages 1-26, November.
    • Handle: RePEc:gam:jijerp:v:16:y:2019:i:22:p:4334-:d:284384
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/16/22/4334/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/16/22/4334/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Sander Kersten & Béatrice Desvergne & Walter Wahli, 2000. "Roles of PPARs in health and disease," Nature, Nature, vol. 405(6785), pages 421-424, May.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Jesús Funuyet-Salas & María Ángeles Pérez-San-Gregorio & Agustín Martín-Rodríguez & Manuel Romero-Gómez, 2021. "Quality of Life and Coping in Nonalcoholic Fatty Liver Disease: Influence of Diabetes and Obesity," IJERPH, MDPI, vol. 18(7), pages 1-15, March.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. W. Wang & W. Xue & X. Xu & B. Jin & X. Zhang, 2016. "Correlations of genes expression in PPAR signalling pathway with porcine meat quality traits," Czech Journal of Animal Science, Czech Academy of Agricultural Sciences, vol. 61(7), pages 333-339.
    2. Jun-Wei Gao & Ling Zeng & An-Qiang Zhang & Xiao Wang & Wei Pan & Ding-Yuan Du & Lian-Yang Zhang & Wei Gu & Jian-Xin Jiang, 2016. "Identification of Haplotype Tag Single-Nucleotide Polymorphisms within the PPAR Family Genes and Their Clinical Relevance in Patients with Major Trauma," IJERPH, MDPI, vol. 13(4), pages 1-11, March.
    3. A. Aparicio-Cecilio & J. Bouda & E.G. Salgado-Hernández & L. Núñez-Ochoa & D.A. Castillo-Mata & A. Gutiérrez-Chávez, 2012. "Effect of 2-methyl-2-phenoxy propionic acid on serum lipid profile and ovarian activity in dairy cows," Czech Journal of Animal Science, Czech Academy of Agricultural Sciences, vol. 57(12), pages 550-556.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:16:y:2019:i:22:p:4334-:d:284384. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.